JP Morgan maintains Gilead Sciences at Overweight, raises price target to $190 from $170

What happened

JP Morgan kept its Overweight rating on Gilead Sciences and raised its price target to $190 from $170, an 11.8% increase. The target was 11.3% above Gilead’s Oct. 30 closing price of $170.68.

Confirmed

Global impact / market context

A higher target signals that JP Morgan sees more potential share-price appreciation, but it is an analyst estimate rather than a company result or guarantee. If investors act on the view, demand for Gilead shares could rise; the article provides no evidence of a market reaction.

Analyst inference

Other recent analyst targets cited range from $175 to $200, while JP Morgan’s new $190 target sits within that range. This shows the update is broadly in line with the reported spread of views, rather than the highest target listed.

Confirmed

What to watch

1. Whether JP Morgan later changes its rating or target would show if its view of Gilead’s expected share value has shifted again. Analyst inference
2. Compare future analyst targets with the reported $175–$200 range; movement beyond it could indicate a change in analyst expectations for Gilead. Analyst inference
3. The article gives no company earnings, sales, costs, or cash-flow information, so it does not establish whether business performance supports the higher target. Confirmed

Evidence

• Original source link unavailable